PharmaResources (Shanghai) Co., Ltd.

Equities

301230

CNE1000065Q9

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
22.24 ^CNY	+1.92%		+1.60%	-19.24%

15/07	Announcement of the Resolution of the Second Extraordinary General Meeting of Shareholders of PharmaRespurces Shanghai	CI
03/07	Tranche Update on PharmaResources Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024.	CI

PharmaResources Co., Ltd. Announces Final Profit Distribution on A Shares for the Year 2023, Payable on 21 June 2024

June 18, 2024 at 01:02 am IST

PharmaResources (Shanghai) Co., Ltd. announced final profit distribution plan to be implemented on A shares cash dividend/10 shares (tax included) of CNY 3.30000000 for the year 2023. Record date: 20 June 2024. Ex-date: 21 June 2024.

Payment date: 21 June 2024.

Latest news about PharmaResources (Shanghai) Co., Ltd.

Announcement of the Resolution of the Second Extraordinary General Meeting of Shareholders of PharmaRespurces Shanghai	15/07	CI
Tranche Update on PharmaResources Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024.	04/07	CI
Shareholder Proposal for Expansion of PharmaResources's Main Business	02/07	CI
PharmaResources Co., Ltd. Announces Final Profit Distribution on A Shares for the Year 2023, Payable on 21 June 2024	18/06	CI
PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023	24/04	CI
PharmaResources Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/04	CI
Tranche Update on PharmaResources Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024.	01/04	CI
PharmaResources Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	19/02	CI
PharmaResources Co., Ltd. authorizes a Buyback Plan.	07/02	CI
Certain A Shares of PharmaResources Co., Ltd. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	01/11	CI
PharmaResources Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/23/25	CI
PharmaResources Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI

Chart PharmaResources (Shanghai) Co., Ltd.

Duration

Period

Chart PharmaResources (Shanghai) Co., Ltd.

More charts

Company Profile

PharmaResources Shanghai Co Ltd is a China-based company mainly engaged in the development and commercial production of new drugs. The Company's main businesses include drug discovery, process research and development and commercial manufacturing business. The drug discovery business includes medicinal chemistry, synthetic chemistry and pharmacokinetics. The process research and development business includes process chemistry and process development as well as bulk drug research. The commercial manufacturing business includes customized manufacturing of new drugs and the research and development, production and sales of proprietary generic drug products. The Company distributes its products to the United States, India and other countries.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for PharmaResources (Shanghai) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.24

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMARESOURCES (SHANGHAI) CO., LTD.	-19.24%	425M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.77%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research